DEA pseudoephedrine proposal would affect about $115 mil. in Warner Wellcome retail sales.
This article was originally published in The Tan Sheet
Executive Summary
DEA PSEUDOEPHEDRINE REG WOULD AFFECT ABOUT $115 MIL. IN WARNER WELLCOME SALES, parent company Warner-Lambert estimated in Dec. 28 comments to the Drug Enforcement Agency. Warner-Lambert complained that DEA's Oct. 31 proposed rule, which would require retailers to report all single sales involving more than 24 grams pseudoephedrine base, would "directly" affect "14 SKUs, including 13 Sudafed and Actifed and one Benadryl Decongestant product with retail sales of approximately $115 mil."